Oxidative Stress in Benign Prostatic Hyperplasia: Mechanisms, Clinical Relevance and Therapeutic Perspectives

Overview

Journal Diseases

Date 2025 Feb 25

PMID 39997060

Authors

Aris Kaltsas

Timoleon Giannakas

Marios Stavropoulos

Zisis Kratiras

Michael Chrisofos

Affiliations

Soon will be listed here.

Abstract

Background/objectives: Benign prostatic hyperplasia (BPH) is among the most common conditions affecting men as they age, resulting in lower urinary tract symptoms (LUTS) that can profoundly impact quality of life. While historically attributed primarily to androgenic imbalances, current evidence implicates additional factors-particularly oxidative stress (OS) and chronic inflammation-in BPH pathogenesis. This review aims to synthesize research on the interplay between OS, inflammation, and hormonal regulation in BPH, emphasizing their clinical relevance and potential therapeutic implications.

Methods: A comprehensive review of peer-reviewed literature was conducted focusing on mechanistic studies, clinical trials, and observational reports. Searches included data on ROS generation, antioxidant capacity, inflammatory mediators, and their contribution to pathological prostatic overgrowth. Potential interventions targeting OS-such as antioxidant supplementation, anti-inflammatory drugs, vitamin D receptor agonists, and phytotherapeutics-were also evaluated for their efficacy and safety profiles.

Results: Chronic inflammation and OS were consistently identified within hyperplastic prostate tissue. Excessive ROS production, diminished antioxidant defense, and sustained cytokine release create a proproliferative and antiapoptotic environment, accelerating disease progression. Metabolic comorbidities (e.g., obesity, insulin resistance) further exacerbate these imbalances. Standard therapies (α-blockers and 5-ARIs) effectively relieve symptoms but do not directly address the oxidative-inflammatory axis. Emerging evidence suggests that pharmacological and dietary approaches targeting OS and inflammation may reduce prostate volume expansion and alleviate LUTS.

Conclusions: Findings indicate that OS and inflammation are key contributors to BPH progression. Incorporating antioxidant and anti-inflammatory strategies alongside conventional treatments holds promise for improving clinical outcomes and patient quality of life. Future research should focus on validating OS-specific biomarkers and optimizing personalized therapy regimens.

References

Tsurusaki T, Aoki D, Kanetake H, Inoue S, Muramatsu M, Hishikawa Y . Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia. J Clin Endocrinol Metab. 2003; 88(3):1333-40. DOI: 10.1210/jc.2002-021015. View

Cho S, Choi E . Apoptotic signaling pathways: caspases and stress-activated protein kinases. J Biochem Mol Biol. 2005; 35(1):24-7. DOI: 10.5483/bmbrep.2002.35.1.024. View

Gradini R, Realacci M, Ginepri A, Naso G, Santangelo C, Cela O . Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol. 1999; 189(2):224-9. DOI: 10.1002/(SICI)1096-9896(199910)189:2<224::AID-PATH422>3.0.CO;2-K. View

Iacopino F, Angelucci C, Lama G, Zelano G, La Torre G, DAddessi A . Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma. Anticancer Res. 2006; 26(3A):1849-54. View

Bechis S, Otsetov A, Ge R, Olumi A . Personalized medicine for the management of benign prostatic hyperplasia. J Urol. 2014; 192(1):16-23. PMC: 4143483. DOI: 10.1016/j.juro.2014.01.114. View

Mahmud S, Tanguay S, Begin L, Franco E, Aprikian A . Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev. 2006; 15(2):158-64. DOI: 10.1097/01.cej.0000197451.02604.25. View

Buck A . Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol. 2004; 172(5 Pt 1):1792-9. DOI: 10.1097/01.ju.0000140503.11467.8e. View

De Marzo A, Platz E, Sutcliffe S, Xu J, Gronberg H, Drake C . Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007; 7(4):256-69. PMC: 3552388. DOI: 10.1038/nrc2090. View

Vickman R, Franco O, Moline D, Vander Griend D, Thumbikat P, Hayward S . The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. Asian J Urol. 2020; 7(3):191-202. PMC: 7385520. DOI: 10.1016/j.ajur.2019.10.003. View

10.

Kramer G, Marberger M . Could inflammation be a key component in the progression of benign prostatic hyperplasia?. Curr Opin Urol. 2005; 16(1):25-9. View

11.

Konig J, Senge T, Allhoff E, Konig W . Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate. 2004; 58(2):121-9. DOI: 10.1002/pros.10317. View

12.

Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D . Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2002; 1(3):157-162. DOI: 10.1038/sj.pcan.4500221. View

13.

Fernandez-Checa J, Kaplowitz N, Garcia-Ruiz C, Colell A, Miranda M, Mari M . GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am J Physiol. 1997; 273(1 Pt 1):G7-17. DOI: 10.1152/ajpgi.1997.273.1.G7. View

14.

Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A . The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013; 112(4):432-41. DOI: 10.1111/bju.12118. View

15.

Saito M, Tsounapi P, Oikawa R, Shimizu S, Honda M, Sejima T . Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH. Sci Rep. 2014; 4:3822. PMC: 3897960. DOI: 10.1038/srep03822. View

16.

Untergasser G, Madersbacher S, Berger P . Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol. 2005; 40(3):121-8. DOI: 10.1016/j.exger.2004.12.008. View

17.

Smith M, Morton R, Barnette K, Sieber P, Malkowicz S, Rodriguez D . Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2010; 184(4):1316-21. PMC: 3047407. DOI: 10.1016/j.juro.2010.06.022. View

18.

Sikka S . Role of oxidative stress response elements and antioxidants in prostate cancer pathobiology and chemoprevention--a mechanistic approach. Curr Med Chem. 2003; 10(24):2679-92. DOI: 10.2174/0929867033456341. View

19.

Lambeth J . Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med. 2007; 43(3):332-47. PMC: 2013737. DOI: 10.1016/j.freeradbiomed.2007.03.027. View

20.

Buck A . Phytotherapy for the prostate. Br J Urol. 1996; 78(3):325-36. DOI: 10.1046/j.1464-410x.1996.00104.x. View